eSynthesis - an automated platform technology for rapid, high-throughput and clonal cell-free synthetic DNA synthesis

_市场拉动_定制DNA和蛋白质的合成对于各行各业的生物技术创新至关重要，对两者的需求正在加速。下一代测序产生了大量的天然DNA代码库，可以利用和定制新的和改进的产品，从治疗性蛋白质到生物工业酶。但英国缺乏国内DNA合成服务，无法提供具有复杂性、速度和可变吞吐量的定制产品，这是研发管道有效运作所必需的。为什么是无细胞？_我们与许多客户都面临着一个关键的瓶颈-传统细菌克隆导致的时间、产量、资源和纯度的损失。无细胞方法实现了自动化、过程简化和高通量，提高了DNA/蛋白质变体合成和筛选的规模。无细胞还可以产生对细胞有毒的分子或表现出新的自然生物化学。我们的创新_我们将建立eSynthesis平台，通过开发组装部件的无细胞克隆扩增技术，利用最先进的酶促DNA合成（EDS）。我们是第一家使用EDS的英国服务提供商，我们准备利用EDS寡核苷酸的上级长度和错误率。我们的目标是复制细胞做得很好，DNA的克隆复制，在一个自动化的无细胞过程，提供速度，成本和吞吐量的好处。我们的使命是引领合成生物学研发的新范式转变，即完全控制分子环境。我们的创新领域包括：（a）避免细胞繁殖的新型质粒DNA扩增技术，（B）自动化、高通量和DNA合成平台，以及（c）生成适用于筛选应用的DNA变体文库。影响_我们的eSynthesis平台将使我们能够：（a）以比现有竞争对手更快、更低的成本提供复杂/难以复制、高度纯化和应用不可知的定制DNA产品，以及（B）利用我们现有的下游无细胞蛋白质合成服务，以其他不可行的高通量筛选表达变体文库。我们对客户的价值主张将是能够通过发现和产品优化管道更快地进行扩展。

_The market pull_Synthesis of custom DNA and proteins is vital for biotechnology innovation across a wide range of industries and demand for both is accelerating. Next-generation sequencing has produced a vast library of natural DNA code that can be harnessed and customised for the engineering of new and improved products, from therapeutic proteins to bio-industrial enzymes. But the UK lacks a domestic DNA synthesis service with the capacity to deliver custom products with the complexity, speed and variant-throughput necessary for R&D pipelines to iterate effectively._Why cell-free?_We share a critical bottleneck with many of our customers - the loss of time, throughput, resource and purity as a result of traditional bacterial cloning. Cell-free approaches enable automation, process miniaturisation and high-throughput, improving the scale at which DNA/protein variants can be synthesised and screened by orders of magnitude. Cell-free also enables production of molecules toxic to cells or exhibiting new-to-nature biochemistries._Our innovation_We will build the eSynthesis platform, exploiting state-of-the-art enzymatic DNA synthesis (EDS) by developing technology for cell-free clonal amplification of assembled parts. We are among the first UK service providers to utilise EDS and we are primed to exploit the superior length and error-rate of EDS oligonucleotides. We aim to reproduce what cells do well, clonal replication of DNA, in an automatable cell-free process that delivers speed, cost and throughput benefits. Our mission is to lead a new paradigm shift in synthetic biology R&D defined by complete control of molecular context.Our areas of innovation will include: (a) novel plasmid DNA amplification technology that avoids cell-based propagation, (b) an automated, high-throughput and DNA synthesis platform, and (c) generation of DNA variant libraries for suitable for screening applications._Impacts_Our eSynthesis platform will enable us to: (a) deliver complex/difficult to replicate, highly-purified and application-agnostic custom DNA products quicker and at lower cost than established competitors, and (b) leverage our existing downstream cell-free protein synthesis service to screen libraries of expressed variants at an otherwise unfeasibly high throughput. Our value proposition to customers will be the ability to iterate faster through discovery and product optimisation pipelines.